Merck's Fosamax caused a 31% increase in the density of spine bones among women who had received parathyroid hormone shots to ward off the brittle bone disease, according to a study in the New England Journal of Medicine. The team found using Fosamax slowed the body's natural process of destroying old bones as the parathyroid hormone from NPS Pharmaceuticals increased bone growth.

Full Story:

Related Summaries